Drug intelligence / Profile preview

epirubicin + pemetrexed

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of epirubicin (an anthracycline topoisomerase II inhibitor) and pemetrexed (a multi-targeted antifolate). This combination has been investigated for the treatment of locally advanced or metastatic breast cancer. While the regimen demonstrated safety, it showed limited efficacy in phase II studies with only 23% of patients achieving partial response, below the predefined efficacy requirements.

Targets

TOP2A (DNA topoisomerase II)TS (Thymidylate synthase)

Beyond the preview

Go deeper on epirubicin + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epirubicin + pemetrexed.

Explore the full profile